Difference in Benefit of Chemotherapy Between Small Cell Lung Cancer Patients with Interstitial Pneumonia and Patients with Non-small Cell Lung Cancer

Overview

Journal Anticancer Res

Specialty Oncology

Date 2015 Feb 11

PMID 25667495

Citations 10

Authors

Kosuke Kashiwabara

Hiroshi Semba

Shinji Fujii

Shinsuke Tsumura

Ryota Aoki

Affiliations

Soon will be listed here.

Abstract

Background: It is not clear whether there is a difference in benefit of chemotherapy between small cell lung cancer (SCLC) patients with pre-existing idiopathic interstitial pneumonias (IIPs) and non-small cell lung cancer (NSCLC) patients with IIPs.

Patients And Methods: We performed a retrospective study of the overall survival (OS) between advanced lung cancer patients with IIPs (n=28) and those without IIPs (n=145).

Results: The OS in NSCLC patients with IIPs was shorter than in those without IIPs (median OS, 10.6 vs. 27.9 months, p=0.008) but the OS in SCLC patients with IIPs was not inferior to that of those without IIPs (12.7 vs. 14.8 months, p=0.835). Multivariate analysis showed that the small number of regimens increased the risk of mortality, instead of pre-existing IIPs.

Conclusion: The continuation of chemotherapy in SCLC patients with IIPs made it possible to have a similar prognosis to that in those without IIPs.

Citing Articles

Prognostic impact of interstitial lung disease on pulmonary high-grade neuroendocrine carcinoma.

Sakai T, Azuma Y, Kusano M, Kato S, Koezuka S, Iyoda A Sci Rep. 2024; 14(1):21274.

PMID: 39261570 PMC: 11390706. DOI: 10.1038/s41598-024-72267-5.

Lung Cancer and Interstitial Lung Diseases.

Drakopanagiotakis F, Krauss E, Michailidou I, Drosos V, Anevlavis S, Gunther A Cancers (Basel). 2024; 16(16).

PMID: 39199608 PMC: 11352559. DOI: 10.3390/cancers16162837.

Acute exacerbation predicting poor outcomes in idiopathic interstitial pneumonia and advanced lung cancer patients undergoing cytotoxic chemotherapy.

Miyamoto A, Michimae H, Nakahara Y, Akagawa S, Nakagawa K, Minegishi Y Sci Rep. 2024; 14(1):10162.

PMID: 38702426 PMC: 11068886. DOI: 10.1038/s41598-024-60833-w.

Efficacy and safety of second-line chemotherapy for patients with advanced non-small cell lung cancer complicated by interstitial lung disease.

Otsuka K, Nokihara H, Mitsuhashi A, Ozaki R, Yabuki Y, Yoneda H Thorac Cancer. 2022; 13(21):2978-2984.

PMID: 36106507 PMC: 9626311. DOI: 10.1111/1759-7714.14645.

Small Cell Lung Cancer in the Course of Idiopathic Pulmonary Fibrosis-Case Report and Literature Review.

Grodkiewicz M, Koziel P, Chmielewska I, Korbel M, Milanowski J Curr Oncol. 2022; 29(7):5077-5083.

PMID: 35877261 PMC: 9318736. DOI: 10.3390/curroncol29070401.